In Silico Biology

Digital bioprocessing
#Bioprocessing #Culture Biosciences #Cytiva #Digitalisation #In Silico Biology

Collaboration seeks to advance upstream bioprocessing 

Culture Biosciences and Cytiva are collaborating to advance innovation in upstream bioprocessing by providing customers greater access to predictive and robust scale-up capabilities.   Together, the companies aim to bring new bioprocess solutions to customers that use digitaliation, in-silico approaches, and virtual monitoring and control of experiments. … Read More

#News

#Biotechnology #Data #Immunology / Virology & Vaccines #In Silico Biology

Sekkei Bio implements system to centralise research data 

Sekkei Bio, an India-based company dedicated to building technologies for drug and vaccine design with global impact, has implemented CDD Vault as the main platform to house its research data.   Sekkei Bio has made progress toward finding therapies for diabetes and pain, and has a management team… Read More

#News

#Analysis #Biologics / Biotechnology #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #Immunology #In Silico Biology #Lead discovery #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Therapeutics

Will the next generation of CAR-T cells be modified using base editing?

By Dr Jamie Freeman Base editing is a potentially transformative technology for engineering DNA in cells that has the potential to generate knockouts or correct certain errors or mutations in the DNA for applications such as cell or gene therapies. Compared with currently-available gene editing methodologies such as CRISPR/Cas9, which… Read More

#Exclusive Content

#Business #Enabling technologies #In Silico Biology #Nanomedicine / nanotechnology #System biology #Systems biology

Evonetix collaborates with imec to scale-up chip-based technology

Evonetix collaborates with imec to scale-up chip-based technology production for third generation DNA synthesis platform. EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced it has partnered with imec, a world-leading research and innovation hub… Read More

#News

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The CRISPR revolution arrives in immuno-oncology

The CRISPR revolution arrives in immuno-oncology By Helen Stewart-Miller and Thomas Hope Volume 21 Issue 2 - Spring 2020 CRISPR-cas9 technology is having an exciting impact on drug discovery as a whole, but more specifically CRISPR presents enormous opportunities in targeted screening for immuno-oncology research. Clustered regularly-interspaced short palindromic repeats… Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Toxicology

Reprogramming the stem cell for a new generation of cures

Reprogramming the stem cell for a new generation of cures By Dr Alex Davenport, Dr Tonya Frolov and Dr Mark Kotter Volume 21 Issue 2 - Spring 2020 The development of new and effective treatments with the potential to cure, or at the very least ease patient suffering, has been… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Microbiome #Molecular medicine #Nanomedicine / nanotechnology #Oncology #Patent Law #Precision medicine #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

2030 Life Sciences and Health in the Digital Age (Part 2)

By Dr Steve Arlington and John Wise As part of its mission to help members anticipate and prepare for changes in the pharmaceutical industry, The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in… Read More

#Exclusive Content

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Business #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #High Content Screening #In Silico Biology #Lead discovery #Lead optimisation #RNA #System biology #Systems biology #Target validation #Toxicology

How Artificial Intelligence is Transforming Drug Design

How Artificial Intelligence is Transforming Drug Design By Dr Mark Roberts and Dr Sam Genway AI could create a streamlined, automated approach to drug discovery, trawling vast datasets to identify targets, find candidate molecules and predict synthesis routes. Getting there will require significant vision, but we are already seeing exciting… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Orphan drugs #Pathology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation

Fail Early, Fail Fast – A phenotypic rescue approach

Fail Early, Fail Fast - A phenotypic rescue approach By Dr Anne-Marie Zuurmond, et al. New disease targets frequently emerge in literature, but the thorough target validation required to consider these targets for a drug discovery programme is often lacking. In pharmacological or genetic perturbation studies using complex biological assays,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene editing #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Medicinal chemistry #Molecular medicine #Oncology #Organic chemistry #Pathology #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics

Automating Automation – How close are we to Artificial Intelligence impact?

Automating Automation - How close are we to Artificial Intelligence impact? By Dr Michael A. Tarselli, Dr Yohann Potier and Dr Alan E. Fletcher In terms of consistency, repeatability, known errors and sheer volume, there exists perhaps no better collection of data for computer learning than that emerging from automated… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #In Silico Biology #Lead discovery #Lead optimisation #Molecular medicine #Precision medicine #Regulatory #RNA #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Application of bioinformatics in support of precision medicine

Application of bioinformatics in support of precision medicine By Mike Furness and John Wise Bioinformatics has played a major role in gene sequencing diagnostics and has been an essential tool to investigate the genetic causes of disease. With the support of new technologies and tools, bioinformatics can play an important… Read More

#Archive

#Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Flow Cytometry #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

Flow Cytometry – The advanced systems overcoming drug discovery pain points

Flow Cytometry - The advanced systems overcoming drug discovery pain points By Helen Stewart-Miller and Dr Richard Massey Flow cytometry is an invaluable technique for the characterisation of highly heterogeneous cell populations. Thanks to improvements in throughput, automation and multichannel detection capabilities, recent years have seen its use expand across… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biomarkers #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Microbiome #Molecular medicine #Oncology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #Screening #Sequencing #Stem cells #System biology #Therapeutics #Toxicology

How Mergers and Acquisitions Will Drive Oncology Research in 2019

How Mergers and Acquisitions Will Drive Oncology Research in 2019 By Dr Michael Seiler 2019 got off to a fast start for oncology drug discovery, with numerous mergers, acquisitions and collaborations announced in quick succession. These ventures provide a window into key trends in oncology research, where investigators are likely… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Cellular & Molecular biology #Chemical engineering #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Organic chemistry #Pharmacology #Regulatory #RNA #Sequencing

Mining Plant Genomes – A modern approach to herbal healing

Mining Plant Genomes - A modern approach to herbal healing By Michelle Vierra Plants are stationary soldiers. Rooted to one spot, they are not able to chase nutrients or flee from herbivores and pathogens. So in addition to the basic metabolites they synthesise for their survival, they produce a diverse… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Gene therapy #Genomics #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Molecular medicine #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Integrated Platform Drug Discovery and Development Companies – Part 2: Comparative analysis

Integrated Platform Drug Discovery and Development Companies - Part 2: Comparative analysis By Dr Stephen Naylor and Dr Kirkwood A. Pritchard Jr Spring 2019 Large pharmaceutical companies have struggled to efficiently implement tools, technologies and platforms into their drug discovery and development (DDD) programmes. More recently there have been attempts… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biochemistry #Bioengineering #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genetics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Oncology #Organic chemistry #Pathology #PCR #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Cutting-edge technologies meet traditional paradigms in assay development

The Future Of Drug Discovery - Cutting-edge technologies meet traditional paradigms in assay development By Dr Roger Bosse With more than 1,500 drugs approved by the Food and Drug Administration (FDA) on the market, the easiest disease targets are already covered (1). Today’s scientists are challenged to find new compounds,… Read More

#Archive